Exagen Inc. XGN Reportable Segment — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s reportable segment — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s reportable segment — D&A?
- Exagen Inc. (XGN) reported reportable segment — D&A of $230K in Q1 2026.
- How has Exagen Inc.'s reportable segment — D&A changed year-over-year?
- Exagen Inc.'s reportable segment — D&A decreased by 10.9% year-over-year, from $258K to $230K.
- What is the long-term trend for Exagen Inc.'s reportable segment — D&A?
- Over 2 years (2023 to 2025), Exagen Inc.'s reportable segment — D&A has grown at a -13.5% compound annual growth rate (CAGR), from $1.43M to $1.07M.
- What does reportable segment — D&A mean?
- The systematic allocation of the cost of tangible and intangible assets over their useful lives within the reportable segment. It represents the non-cash consumption of the segment's capital investments in diagnostic equipment and technology.